Syndax Capex To Revenue vs Ebit Per Revenue Analysis

SNDX Stock

USD 16.72 0.21 1.27%

Syndax Pharmaceuticals financial indicator trend analysis is much more than just breaking down Syndax Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Syndax Pharmaceuticals is a good investment. Please check the relationship between Syndax Pharmaceuticals Capex To Revenue and its Ebit Per Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Syndax Pharmaceuticals Capex To Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Syndax Pharmaceuticals' Capex To Revenue and Ebit Per Revenue is -0.54. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Syndax Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Syndax Pharmaceuticals' Capex To Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Syndax Pharmaceuticals are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Capex To Revenue i.e., Syndax Pharmaceuticals' Capex To Revenue and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

-0.54

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Ebit Per Revenue

Most indicators from Syndax Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Syndax Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.At this time, Syndax Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.3 B in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 137.9 M in 2024.

Syndax Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock Total Equity	Common Stock	Other Liab
Total Assets		-0.3	0.92	0.76	1.0	0.91	0.9	-0.93	-0.93	0.88	0.93	0.84	0.32	1.0	0.31	0.94	-0.17	0.68	0.97	0.63	0.93	1.0	-0.64	0.97	0.98	0.47
Short Long Term Debt Total	-0.3		-0.33	-0.15	-0.31	-0.38	-0.36	0.26	0.51	-0.4	-0.18	-0.42	-0.15	-0.3	0.42	-0.35	0.11	0.01	-0.37	0.0	-0.34	-0.29	0.5	-0.24	-0.28	-0.76
Other Current Liab	0.92	-0.33		0.9	0.92	0.9	0.95	-0.92	-0.88	0.94	0.91	0.96	0.19	0.91	0.34	0.81	-0.4	0.42	0.92	0.58	0.91	0.91	-0.55	0.9	0.93	0.33
Total Current Liabilities	0.76	-0.15	0.9		0.75	0.74	0.85	-0.78	-0.7	0.81	0.8	0.89	0.03	0.75	0.59	0.63	-0.5	0.23	0.77	0.65	0.75	0.75	-0.15	0.74	0.78	0.14
Total Stockholder Equity	1.0	-0.31	0.92	0.75		0.9	0.9	-0.93	-0.92	0.87	0.92	0.84	0.35	1.0	0.29	0.95	-0.18	0.69	0.96	0.6	0.93	1.0	-0.65	0.97	0.98	0.47
Property Plant And Equipment Net	0.91	-0.38	0.9	0.74	0.9		0.82	-0.9	-0.93	0.96	0.88	0.77	0.19	0.91	0.27	0.82	-0.17	0.59	0.95	0.61	0.99	0.91	-0.68	0.94	0.94	0.49
Current Deferred Revenue	0.9	-0.36	0.95	0.85	0.9	0.82		-0.82	-0.81	0.82	0.81	0.95	0.42	0.89	0.37	0.86	-0.57	0.48	0.86	0.44	0.86	0.89	-0.47	0.83	0.88	0.25
Net Debt	-0.93	0.26	-0.92	-0.78	-0.93	-0.9	-0.82		0.88	-0.92	-0.99	-0.83	0.0	-0.93	-0.23	-0.77	0.13	-0.46	-0.91	-0.65	-0.91	-0.93	0.61	-0.91	-0.91	-0.45
Retained Earnings	-0.93	0.51	-0.88	-0.7	-0.92	-0.93	-0.81	0.88		-0.91	-0.85	-0.8	-0.23	-0.93	-0.15	-0.88	0.05	-0.59	-0.98	-0.66	-0.92	-0.93	0.72	-0.94	-0.95	-0.64
Accounts Payable	0.88	-0.4	0.94	0.81	0.87	0.96	0.82	-0.92	-0.91		0.91	0.85	0.03	0.87	0.24	0.74	-0.21	0.39	0.91	0.62	0.94	0.87	-0.64	0.89	0.9	0.48
Cash	0.93	-0.18	0.91	0.8	0.92	0.88	0.81	-0.99	-0.85	0.91		0.82	-0.02	0.92	0.28	0.75	-0.13	0.45	0.9	0.66	0.9	0.92	-0.56	0.91	0.91	0.39
Non Current Assets Total	0.84	-0.42	0.96	0.89	0.84	0.77	0.95	-0.83	-0.8	0.85	0.82		0.21	0.83	0.29	0.74	-0.55	0.26	0.82	0.46	0.79	0.83	-0.43	0.77	0.82	0.3
Non Currrent Assets Other	0.32	-0.15	0.19	0.03	0.35	0.19	0.42	0.0	-0.23	0.03	-0.02	0.21		0.33	0.19	0.59	-0.31	0.67	0.26	-0.14	0.24	0.33	-0.28	0.29	0.32	0.02
Cash And Short Term Investments	1.0	-0.3	0.91	0.75	1.0	0.91	0.89	-0.93	-0.93	0.87	0.92	0.83	0.33		0.31	0.95	-0.15	0.7	0.97	0.63	0.93	1.0	-0.64	0.98	0.98	0.48
Common Stock Shares Outstanding	0.31	0.42	0.34	0.59	0.29	0.27	0.37	-0.23	-0.15	0.24	0.28	0.29	0.19	0.31		0.3	-0.32	0.29	0.29	0.59	0.31	0.31	0.35	0.33	0.34	-0.29
Short Term Investments	0.94	-0.35	0.81	0.63	0.95	0.82	0.86	-0.77	-0.88	0.74	0.75	0.74	0.59	0.95	0.3		-0.16	0.82	0.91	0.53	0.85	0.95	-0.64	0.92	0.93	0.49
Non Current Liabilities Total	-0.17	0.11	-0.4	-0.5	-0.18	-0.17	-0.57	0.13	0.05	-0.21	-0.13	-0.55	-0.31	-0.15	-0.32	-0.16		0.15	-0.13	0.21	-0.21	-0.15	-0.18	-0.08	-0.16	0.42
Other Current Assets	0.68	0.01	0.42	0.23	0.69	0.59	0.48	-0.46	-0.59	0.39	0.45	0.26	0.67	0.7	0.29	0.82	0.15		0.65	0.39	0.63	0.7	-0.52	0.73	0.7	0.28
Other Stockholder Equity	0.97	-0.37	0.92	0.77	0.96	0.95	0.86	-0.91	-0.98	0.91	0.9	0.82	0.26	0.97	0.29	0.91	-0.13	0.65		0.67	0.95	0.97	-0.64	0.98	0.99	0.51
Total Liab	0.63	0.0	0.58	0.65	0.6	0.61	0.44	-0.65	-0.66	0.62	0.66	0.46	-0.14	0.63	0.59	0.53	0.21	0.39	0.67		0.59	0.63	-0.19	0.68	0.65	0.38
Property Plant And Equipment Gross	0.93	-0.34	0.91	0.75	0.93	0.99	0.86	-0.91	-0.92	0.94	0.9	0.79	0.24	0.93	0.31	0.85	-0.21	0.63	0.95	0.59		0.93	-0.66	0.95	0.95	0.45
Total Current Assets	1.0	-0.29	0.91	0.75	1.0	0.91	0.89	-0.93	-0.93	0.87	0.92	0.83	0.33	1.0	0.31	0.95	-0.15	0.7	0.97	0.63	0.93		-0.65	0.98	0.98	0.48
Short Term Debt	-0.64	0.5	-0.55	-0.15	-0.65	-0.68	-0.47	0.61	0.72	-0.64	-0.56	-0.43	-0.28	-0.64	0.35	-0.64	-0.18	-0.52	-0.64	-0.19	-0.66	-0.65		-0.66	-0.65	-0.6
Common Stock Total Equity	0.97	-0.24	0.9	0.74	0.97	0.94	0.83	-0.91	-0.94	0.89	0.91	0.77	0.29	0.98	0.33	0.92	-0.08	0.73	0.98	0.68	0.95	0.98	-0.66		0.99	0.45
Common Stock	0.98	-0.28	0.93	0.78	0.98	0.94	0.88	-0.91	-0.95	0.9	0.91	0.82	0.32	0.98	0.34	0.93	-0.16	0.7	0.99	0.65	0.95	0.98	-0.65	0.99		0.44
Other Liab	0.47	-0.76	0.33	0.14	0.47	0.49	0.25	-0.45	-0.64	0.48	0.39	0.3	0.02	0.48	-0.29	0.49	0.42	0.28	0.51	0.38	0.45	0.48	-0.6	0.45	0.44

Click cells to compare fundamentals

Syndax Pharmaceuticals Account Relationship Matchups

Syndax Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	63.5M	300.6M	449.7M	497.2M	612.9M	643.5M
Other Current Liab	10.2M	11.2M	14.7M	24.3M	47.1M	49.4M
Total Current Liabilities	18.4M	18.9M	20.7M	29.1M	58.1M	61.0M
Total Stockholder Equity	31.6M	252.2M	408.4M	467.4M	554.2M	581.9M
Property Plant And Equipment Net	997K	482K	1.3M	1.1M	1.5M	1.6M
Net Debt	(23.7M)	(94.7M)	(201.0M)	(73.2M)	(293.8M)	(279.1M)
Retained Earnings	(495.5M)	(568.6M)	(543.7M)	(693.0M)	(902.4M)	(857.3M)
Accounts Payable	6.2M	3.5M	5.7M	4.4M	10.0M	10.5M
Cash	24.6M	115.2M	222.0M	74.4M	295.4M	310.2M
Non Current Assets Total	1.2M	1.7M	1.3M	16.0M	32.0M	33.6M
Non Currrent Assets Other	82K	1.2M	983K	9.4M	680K	646K
Cash And Short Term Investments	59.8M	293.1M	439.9M	481.3M	577.6M	606.5M
Common Stock Shares Outstanding	30.5M	41.3M	53.6M	60.8M	70.4M	38.8M
Short Term Investments	35.2M	177.8M	218.0M	410.0M	282.2M	296.3M
Liabilities And Stockholders Equity	63.5M	300.6M	449.7M	497.2M	612.9M	643.5M
Non Current Liabilities Total	13.6M	29.6M	20.6M	722K	588K	558.6K
Other Current Assets	763K	5.6M	7.9M	9.9M	2.1M	2.7M
Other Stockholder Equity	527.1M	820.8M	952.0M	1.2B	1.5B	1.5B
Total Liab	31.9M	48.4M	41.3M	29.8M	58.7M	34.5M
Property Plant And Equipment Gross	997K	482K	1.7M	1.5M	1.9M	2.0M
Total Current Assets	62.3M	298.9M	448.4M	481.3M	580.9M	609.9M
Accumulated Other Comprehensive Income	(310K)	(4K)	45K	(806K)	218K	228.9K
Short Term Debt	478K	2.6M	362K	439K	1.0M	994.7K
Common Stock	3K	5K	6K	7K	8K	8.4K
Other Liab	17.1M	14.8M	13.1M	11.6M	13.4M	14.2M
Net Tangible Assets	31.6M	252.2M	408.4M	467.4M	537.6M	564.4M
Other Assets	219K	0.0	1.6M	922K	829.8K	472.8K
Net Receivables	116K	175K	429K	4.1M	1.2M	795.6K
Inventory	1.7M	5.3M	7.7M	(4.3M)	2.0M	1.6M
Property Plant Equipment	997K	192K	278K	1.1M	1.2M	1.3M
Retained Earnings Total Equity	(439.4M)	(495.5M)	(568.6M)	(543.7M)	(489.3M)	(513.8M)
Capital Surpluse	492.5M	527.1M	820.8M	952.0M	1.1B	669.6M
Non Current Liabilities Other	136K	5K	11.7M	711K	817.7K	776.8K
Net Invested Capital	31.6M	272.3M	428.3M	467.4M	554.2M	300.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syndax Capex To Revenue vs Ebit Per Revenue Analysis

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Ebit Per Revenue

Syndax Pharmaceuticals fundamental ratios Correlations

Syndax Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Syndax Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Syndax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock	- 0.95	Retained Earnings
Common Stock Total Equity	- 0.94	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.93	Retained Earnings